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Abstract: Current diagnostics for tuberculosis (TB) only manage to confirm a small proportion of
children with TB and require respiratory samples, which are difficult to obtain. There is a need
for non-invasive biomarker-based tests as an alternative to sputum testing. Fujifilm SILVAMP TB
lipoarabinomannan (FujiLAM), a lateral-flow test to detect lipoarabinomannan in urine, is a novel
non-sputum-based point-of-care diagnostic reported to have increased sensitivity for the diagnosis
of TB among human immunodeficiency virus (HIV)-infected adults. We evaluate the performance
of FujiLAM in children with presumptive TB. Fifty-nine children attending a paediatric hospital
in Haiti with compatible signs and symptoms of TB were examined using Xpert MTB/RIF, smear
microscopy and X-rays, and classified according to the certainty of diagnosis into bacteriologically
confirmed TB (n = 5), unconfirmed TB (bacteriologically negative, n = 50) and unlikely TB (n = 4).
Healthy children (n = 20) were enrolled as controls. FujiLAM sensitivity and specificity were 60%
and 95% among children with confirmed TB. FujiLAM’s high specificity and its characteristics as a
point-of-care indicate the test has a good potential for the diagnosis of TB in children.
Keywords: tuberculosis; diagnosis; lipoarabinomannan; LAM; children; urine; point-of-care
1. Introduction
Tuberculosis (TB) is a major cause of morbidity and mortality in children [1]. However,
the paucibacillary nature of TB in children and the difficulty of obtaining respiratory
samples create significant barriers for diagnosis [2]. Most children with TB, especially in
countries with high TB burden [3], are not bacteriologically confirmed, or are missed [3].
The lack of reliable diagnostic methods has highlighted the need for non-sputum-based
tests for childhood TB [4,5].
In recent years, attempts have been made to develop diagnostic tests based on the
detection of lipoarabinomannan (LAM) antigen, a lipoglycan and virulence factor in
the bacteria genus Mycobacterium present in the outer cell wall, which is released from
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metabolically active or degenerating bacterial cells. As LAM is heat stable, filtered by
the kidney and detectable in the urine of people with overt TB, test prototypes have
attempted to identify LAM in urine since the 1930s [6,7]. Until recently, urine-based LAM
prototypes have had low sensitivity and performed better in individuals co-infected with
human immunodeficiency virus (HIV) and advanced immunosuppression [8]. Although
the biological mechanisms for the better performance in HIV-positive individuals are not
fully understood, the higher concentration of LAM in the urine could be due to a greater
difficulty in containing Mycobacterium tuberculosis with subsequent hematogenous spread
to the kidneys or to a higher body burden of M. tuberculosis [9–12]. Compared to the
Alere Determine TB-LAM assay, with a reported sensitivity of about 40% for detecting
TB in HIV-infected patients [13], a new assay is reported to have higher sensitivity to
detect LAM in both HIV-infected and uninfected patients [14,15]. The assay, the Fujifilm
SILVAMP TB LAM (FujiLAM, Fujifilm, Tokyo, Japan), combines high-affinity monoclonal
antibodies against M. tuberculosis-specific LAM epitopes and a silver amplification step to
increase the visibility of the test and control lines [15]. However, data on its performance
in children is limited, and we report here its performance in a case series of children with
signs and symptoms of presumptive TB. TB in children has more disseminated clinical
presentations than adults because of their poor containment of TB. In addition, children
have difficulty in expectorating sputum, and assays that use non-sputum samples could be
useful, particularly in young children [2,11,16–18].
2. Materials and Methods
This was a retrospective case series of the bio-banked urine samples of 59 children
with signs and symptoms compatible with TB, and of 20 healthy control children. Children
were enrolled prospectively between August 2015 and December 2016 [19]. The children
with presumptive TB were between 0 and 14 years old, and were enrolled when attending
the Saint Damien paediatric reference hospital in Port-au-Prince, Haiti. Children were
initially identified by the diagnostic clinics and enrolled opportunistically. This is a case
series, as we did not estimate the number of children required and instead enrolled as many
children being investigated for TB as possible over a period of sixteen months. The healthy
children, enrolled as controls, were attending a primary school in the same neighbourhood
of the hospital and were between 5 and 8 years old. The objective of including a control
group was to explore whether any of the children without symptoms of TB had a positive
FujiLAM test to better characterize the specificity of the test.
After obtaining informed parental consent, we collected clinical and demographic
data, vaccination history (including Bacillus Calmette-Guérin (BCG)) and information
about current and previous medications. Children were excluded if they had known
immunodeficiencies, were receiving immunosuppressive treatment, or if they had re-
ceived anti-TB treatment for two or more weeks before enrolment. Tuberculin skin tests
(TSTs) were performed by a trained technician using 0.1 mL of Tubersol (bioequivalent
to 5 Tuberculin Units; Sanofi Pasteur, Canada) and were considered TST positive if they
had ≥10 mm induration in the presence of a BCG scar or ≥5 mm in non-BCG-vaccinated
children with no known contact with adults with TB [20]. Three millilitres of blood was
obtained for the QuantiFERON-TB Gold In-Tube test (QFT-GIT, Qiagen, Germany [21]),
following the manufacturer’s instructions.
Children with presumptive TB underwent anterior–posterior chest X-rays, which
were read by two radiologists blinded to the child’s condition, and a third reader resolved
reading disagreements. Three consecutive sputum samples obtained by induced or na-
sopharyngeal/nasogastric aspiration were examined by fluorescence smear microscopy
stained with auramine, and children with positive smear microscopy or abnormal X-rays
underwent Xpert MTB/RIF (Cepheid, Sunnydale, CA, USA) following local diagnostic
algorithms. No culture facilities were available. Children with lymph node adenopathy
underwent biopsies for histological examination.
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Children with presumptive TB were classified using the clinical case definitions
into confirmed, unconfirmed, and unlikely TB [22]. Children were classified as having
confirmed TB if bacteriologically confirmed by Xpert MTB/RIF; as unconfirmed TB if there
was no bacteriological confirmation but a positive TST or QFT-GIT and at least one of
the clinical criteria of the Clinical Case Definitions (i.e., X-rays consistent with TB, signs
and symptoms of TB, close TB exposure, or positive response to TB treatment), or at least
two clinical criteria if the TST and QFT-GIT results were negative; and unlikely TB if the
child had only evidence of M. tuberculosis infection or presented only one clinical criterion
compatible with TB. Enrolled school children had a negative TST and QFT-GIT, and no
signs or symptoms of TB. Those with positive TST or symptoms compatible with TB were
referred to the hospital for TB screening and were not included as controls.
Participants were asked to provide a midstream urine sample on-site, collected in
sterile plastic containers, or in urine bags for children <1 year, and stored at room tempera-
ture if they were processed at the time of collection, or stored in a refrigerator if processed
in batches at the end of the day. Urine samples were aliquoted (2 mL) into cryovials and
kept at −20 ◦C until processing in Badalona, Spain (IGTP). To test with FujiLAM, urine
samples were thawed at room temperature, mixed with a vortex, and processed following
the manufacturer’s instructions steps: first, the reagent tube was filled with urine up to
the indicator line, mixed and left to incubate for 40 min at room temperature. The tube
was then mixed, two drops of urine were added to the test device, and the first button was
pressed. After 3–10 min of incubation, the second button was pressed to release the silver
ions around the gold-conjugated antibody. The results were then read after one minute
by two investigators blinded to the participants’ TB status, following the manufacturer’s
instructions. If readers disagreed on the presence of test lines, the test was repeated once.
Categorical variables were described by frequencies and percentages, and quanti-
tative variables described using means and 95% confidence intervals (CIs) if normally
distributed, and medians and interquartile ranges (IQRs) if not normally distributed. We
used Fisher’s exact test, chi-square and Kruskal–Wallis tests to compare between groups,
and p-values < 0.05 were considered statistically significant. The sensitivity, specificity, and
predictive values of FujiLAM were estimated using Xpert MTB/RIF as the microbiological
reference standard, and against a composite of the combination of clinical diagnosis and
Xpert MTB/RIF. Diagnostic accuracy was calculated for microbiologically confirmed cases
vs. cases with unconfirmed TB, unlikely TB or controls, and for the composite reference
standard vs. unlikely TB and controls. Statistical analysis was performed using SPSS (SPSS
version 26.0, SPSS Inc, Chicago, IL, USA). The World Health Organization (WHO) Anthro
3.2.2 (<5 years) and Anthro Plus 1.0.4 (≥5 years) were used to estimate z-scores [23,24]. Un-
dernutrition was classified as a weight-for-age z-score < −2 (or as body mass index-for-age
z-score < −2 for children above 10 years) and stunting as a height-for-age z-score < −2.
Informed consent was obtained from the parents or legal guardians. The study was
approved by the Ethics Committee of the University of Barcelona and the Haiti National
Ethics Committee (reference number IRB00003099).
3. Results
Eighty-two children were enrolled, of which three were excluded due to insufficient
urine volumes. Of the 59 with presumptive TB, 5 were bacteriologically confirmed, 50
had unconfirmed but clinically diagnosed TB, and 4 were deemed not to have TB. The
additional 20 were healthy controls. Demographic characteristics of the study groups are
shown in Table 1. Fifty-one (64.6%) children were male, with a median age of 76 (IQR
58–121) months. Their median body mass index was 14.80 (SD ± 2.4); eighteen (30.5%)
reported recent and severe weight loss and twelve (20.7%) reported stunted growth. Fifty-
six (75.7%) had received the BCG vaccine and had a BCG scar. FujiLAM results are shown
in Table 2. Eight (10.1%) samples were positive and seventy-one (89.9%) negative (Table 2).
Three of the positive samples belonged to children with bacteriologically confirmed TB,
three to children with unconfirmed TB, one to a child with unlikely TB and one to a
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control. Among the six FujiLAM-positive children with bacteriologically confirmed and
unconfirmed TB, four had intrathoracic and one both intrathoracic and TB spondylitis. If
Xpert MTB/RIF was considered the reference standard, the sensitivity of FujiLAM was
60% (95% CI 17–93) and the specificity, considering the control group, 95% (95% CI 73–100).
If confirmed and unconfirmed TB were compared against unlikely TB and controls, the
sensitivity was 11% (95%CI 5–23) and the specificity 92% (95% CI 72–99). Five (71.4%) of
the seven FujiLAM-positive children with presumptive TB were underweight and four
(66.7%) were stunted (p = 0.023 and p = 0.014, respectively). The one case of disagreement
of FujiLAM assays between the two readers was resolved after repeating the test.
Table 1. Demographic and clinical characteristics of participants.
Overall (n = 79) Confirmed TB(n = 5)
Unconfirmed







Female 28 (35%) 1 (20%) 21 (42%) 1 (25%) 5 (25%) 0.530
Male 51 (65%) 4 (80%) 29 (58%) 3 (75%) 15 (75%)
Median age (IQR) months 76 (58–121) 95 (51–128) 76 (51–122) 152 (98–165) 70 (58–94) 0.109
<5 yrs. 24 (30%) 1 (20%) 16 (32%) 0 (0%) 7 (35%) 0.654
≥5 yrs. 55 (70%) 4 (80%) 34 (68%) 4 (100%) 13 (65%)
BCG scar (n = 74) 56 (76%) 3 (60%) 35 (78%) 2 (50%) 16 (80%) 0.390
TST or QFT-GIT positive 55 (93%) 5 (100%) 46 (92%) 4 (100%) 0 (0%) 1.000
TST positive 52 (88%) 4 (80%) 44 (88%) 4 (100%) 0 (0%) 0.707
QFT-GIT positive (n = 53) 37 (70%) 5 (100%) 28 (64%) 4 (100%) 0 (0%) 0.101
TB contact 50 (85%) 1 (20%) 45 (90%) 4 (100%) 0 (0%) 0.002
Cough 48 (81%) 5 (100%) 39 (78%) 4 (100%) 0 (0%) 0.491
Fever 40 (68%) 4 (80%) 34 (68%) 2 (50%) 0 (0%) 0.718
Lethargy 4 (7%) 3 (60%) 1 (2%) 0 (0%) 0 (0%) 0.002
Weight loss (n = 56) 19 (34%) 3 (60%) 15 (32%) 1 (25%) 0 (0%) 0.517
Adenopathy 22 (37%) 4 (80%) 18 (36%) 0 (0%) 0 (0%) 0.046
Underweight (n = 74) 18 (31%) 3 (60%) 15 (30%) 0 (0%) 0 (0%) 0.201
Stunted (n = 58) a 12 (21%) 2 (40%) 9 (18.4%) 1 (25%) 0.418
X-ray consistent with TB 28 (46%) 5 (100%) 23 (46%) 0 (0%) NA 0.161
Positive smear-microscopy
(n = 52) 10 (19%) 3 (60%) 7 (16%) 0 (0%) 0 (0%) 0.062
Treatment completed 50 (85%) 5 (100%) 45 (90%) 0 (0%) NA <0.001
Lost to follow-up 8 (14%) 0 (0%) 4 (8%) 4 (100%) NA
Died 1 (2%) 0 (0%) 1 (2%) 0 (0%) NA
Intrathoracic 18 (31%) 2 (40%) 16 (32%) 0 (0%) NA <0.001
Extra-thoracic 7 (12%) 0 (0%) 7 (14%) 0 (0%) NA
Both 4 (7%) 3 (60%) 1 (2%) 0 (0%) NA
Not defined 30 (51%) 0 (0%) 26 (52%) 4 (100%) NA
IQR: interquartile range; BCG: Bacillus Calmette-Guérin; TST: tuberculin skin test; QFT: QuantiFERON-TB Gold. Malnutrition defined
as weight-for-age z-score < −2 for children under 10 years old and body mass index -for-age z-score < −2 for children above 10 years.
Stunting was defined as height-for-age < −2. a Controls have no results on stunting because height measurements were not taken.
Table 2. FujiLAM results by study group.
FujiLAM
Positive n (%) Negative n (%) Total
Confirmed TB 3 (60%) 2 (40%) 5
Unconfirmed TB 3 (6%) 47 (94%) 50
Unlikely TB 1 (25%) 3 (75%) 4
Controls 1 (5%) 19 (95%) 20
All 8 (10.1%) 71 (89.9%) 79
4. Discussion
We evaluated the FujiLAM test in a case series of children attending the hospital
with signs and symptoms of presumptive TB. Among children with bacteriologically
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confirmed TB, the test had a sensitivity of 60%, with a high specificity of 95%. However,
the case series is small, which resulted in wide and overlapping 95% CI, and therefore
larger studies are needed to confirm our findings. The current LAM assay (AlereLAM)
recommended by the WHO in adults [8] and children [25,26] is only recommended for
severely immunosuppressed adults with HIV and CD4 counts <100 cells/µL [8]. Therefore,
a test that performs well in HIV-uninfected patients would be a significant improvement.
Unlike its predecessor, FujiLAM combines a pair of high-affinity monoclonal antibodies
targeting largely M. tuberculosis-specific LAM epitopes and a silver amplification step to
improve the visibility of the test and control lines, allowing the detection of much lower
LAM concentrations in urine [6,15]. Furthermore, the FujiLAM test identified three more
children who had a clinical diagnosis of TB but could not be bacteriologically confirmed,
which would have lent more support to the decision to treat.
Children have a high risk of developing disseminated forms of TB, and the hematoge-
nous and lymphatic spread of M. tuberculosis is likely to result in high amounts of LAM
in urine [2,9]. However, few studies have reported the performance of FujiLAM in chil-
dren [27,28]. A multicentre study in four African countries reported a relatively high
sensitivity of 67.5% in HIV-negative children [28], but a cohort study in South Africa
reported a lower sensitivity of 38.8% [27]. The authors concluded that the differences in
their results may have been due to the severity of the TB episodes, and that some of the
studies included a high proportion of malnourished children [28]. It has been reported that
LAM detection in urine is associated to the overall amount of M. tuberculosis in the body,
as well as the severity of the disease [10,29]. In our study, sensitivity was higher among
bacterially confirmed cases, who are likely to have more advanced disease stages, while
sensitivity was lower when children with a clinical diagnosis were included. It is unlikely
that all children with a clinical diagnosis of TB had TB (and thus some were misclassified),
and it is thus difficult to classify a negative FujiLAM test as false negative. Furthermore,
the number of positive cases was proportionally higher among underweight and stunted
children [30–32]. Malnutrition has an impact in the several faces of the immune response
against infections, including TB; this limits the contention capacity of the bacilli, increasing
the amount of LAM in urine samples and, therefore, the sensitivity of the LAM tests [28].
FujiLAM specificity was high, which is consistent with previous findings in adults and chil-
dren using microbiological (95%) and composite reference standards (91.7%) [10,27,28,33,34].
Although the test did not reach the 98% specificity recommended by the WHO, our sample
size is not sufficiently powered to make this distinction and the 95% CI overlap with this
value [35].
The FujiLAM’s main advantage is its urine-based format, making an easy to do
and non-invasive test without the need for additional instrumentation [10], generating
opportunities to diagnose TB in patients who do not excrete bacilli, such as people with
extrapulmonary or military TB, HIV and children [4]. Especially among children, the
test may be able to add value to clinical decision-making as a rule in test for TB, in our
study effectively doubling the number of children treated who had confirmation of TB
disease. To our knowledge, there are no studies evaluating the economic impact of LAM
testing within the diagnostic algorithms for paediatric TB [36]. The inclusion of a test with
the performance of the FujiLAM assay could simplify these algorithms and potentially
diagnose a greater number of children with TB and increase the number of children
initiating specific therapy [37]. Our study has significant limitations, including its small
sample size—especially the small number of children with bacteriologically confirmed TB,
which resulted in underpowered estimates. In addition, we did not culture the samples, and
Xpert MTB/RIF and clinical diagnosis were used as reference standards. Xpert MTB/RIF
is known to have lower sensitivity than culture [22], and thus it is likely it underestimated
the number of children with bacteriologically confirmed TB. Other limitations concern
retrospective testing of stored samples; however, studies using the FujiLAM test have
shown good agreement between fresh and frozen urine samples [31,38].
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In conclusion, FujiLAM had moderate sensitivity and high specificity in children
compared to Xpert MTB/RIF, can process samples that are easier to collect than sputum,
and can add a level of certainty to clinical diagnosis. These performance characteristics
and the test’s operational characteristics would facilitate a rapid diagnosis in non-sputum
samples in children—especially in low- and middle-income countries, where facilities
available are limited. More extensive evaluations in children are warranted.
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